| Challenges for NHS hospitals during covid-19 epidemic J Willan, AJ King, K Jeffery, N Bienz BMJ 368, 2020 | 294 | 2020 |
| What is CRISPR/Cas9? M Redman, A King, C Watson, D King Archives of Disease in Childhood-Education and Practice 101 (4), 213-215, 2016 | 270 | 2016 |
| Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors E Di Angelantonio, SG Thompson, S Kaptoge, C Moore, M Walker, ... The Lancet 390 (10110), 2360-2371, 2017 | 260 | 2017 |
| Care of haematology patients in a COVID‐19 epidemic J Willan, AJ King, S Hayes, GP Collins, A Peniket British journal of haematology 189 (2), 241, 2020 | 102 | 2020 |
| Multiple myeloma in the very elderly patient: challenges and solutions J Willan, TA Eyre, F Sharpley, C Watson, AJ King, K Ramasamy Clinical interventions in aging, 423-435, 2016 | 60 | 2016 |
| Neutropenic sepsis: management and complications RT Clarke, T Jenyon, V van Hamel Parsons, AJ King Clinical medicine 13 (2), 185, 2013 | 43 | 2013 |
| Potential new approaches to the management of the Hb Bart’s hydrops fetalis syndrome: the most severe form of α-thalassemia AJ King, DR Higgs Hematology 2014, the American Society of Hematology Education Program Book …, 2018 | 29 | 2018 |
| Pericardiocentesis in contemporary practice. R Inglis, AJ King, M Gleave, W Bradlow, D Adlam The Journal of invasive cardiology 23 (6), 234-239, 2011 | 29 | 2011 |
| Question 2: Should children who have a febrile seizure be screened for iron deficiency? D King, A King Archives of disease in childhood 99 (10), 960-964, 2014 | 28 | 2014 |
| Longer-term efficiency and safety of increasing the frequency of whole blood donation (INTERVAL): extension study of a randomised trial of 20 757 blood donors S Kaptoge, E Di Angelantonio, C Moore, M Walker, J Armitage, ... The Lancet Haematology 6 (10), e510-e520, 2019 | 27 | 2019 |
| Robust CRISPR/Cas9 genome editing of the HUDEP-2 erythroid precursor line using plasmids and single-stranded oligonucleotide donors G Moir-Meyer, PL Cheong, AA Olijnik, J Brown, S Knight, A King, R Kurita, ... Methods and protocols 1 (3), 28, 2018 | 27 | 2018 |
| Reactivation of a developmentally silenced embryonic globin gene AJ King, D Songdej, DJ Downes, RA Beagrie, S Liu, M Buckley, P Hua, ... Nature communications 12 (1), 4439, 2021 | 25 | 2021 |
| How do we use electronic clinical decision support and feedback to promote good transfusion practice S Staples, RA Salisbury, AJ King, P Polzella, G Bakhishli, J Staves, ... Transfusion 60 (8), 1658-1665, 2020 | 19 | 2020 |
| Managing multiple myeloma in the over 70s: a review AJ King, S Gooding, K Ramasamy Maturitas 80 (2), 148-154, 2015 | 15 | 2015 |
| An integrated platform to systematically identify causal variants and genes for polygenic human traits DJ Downes, R Schwessinger, SJ Hill, L Nussbaum, C Scott, ME Gosden, ... BioRxiv, 813618, 2019 | 13 | 2019 |
| Classical Hodgkin's lymphoma: past, present and future perspectives TA Eyre, AJ King, GP Collins British Journal of Hospital Medicine (2005) 74 (11), 612-618, 2013 | 13 | 2013 |
| FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML J Othman, N Potter, K Mokretar, D Taussig, A Khan, P Krishnamurthy, ... Leukemia 37 (10), 2066-2072, 2023 | 11 | 2023 |
| Obstructive sleep apnoea does not lead to clinically significant erythrocytosis AJ King, T Eyre, T Littlewood Bmj 347, 2013 | 10 | 2013 |
| Scalable in vitro production of defined mouse erythroblasts HS Francis, CL Harold, RA Beagrie, AJ King, ME Gosden, JW Blayney, ... Plos one 17 (1), e0261950, 2022 | 8 | 2022 |
| Challenges for NHS hospitals during covid-19 epidemic. BMJ, 368, m1117 J Willan, AJ King, K Jeffery, N Bienz | 7 | 2020 |
Toby A. EyreDepartment of Haematology, Oxford University Hospitals NHS TrustVerified email at ouh.nhs.uk
